Triple therapy 'potentially best option' for stable COPD patients

Triple therapy with a long-acting muscarinic antagonist (LAMA), long-acting beta agonist (LABA) and inhaled corticosteroid (ICS) is associated with a lower risk of exacerbations than single or dual inhaled therapy in patients with stable COPD, according to a meta-analysis of 219 trials.

by Chloe Harman
The optimal inhaled COPD treatment regimen for reducing exacerbations, mortality, and adverse events is unknown. | GCA/SCIENCE PHOTO LIBRARY
The optimal inhaled COPD treatment regimen for reducing exacerbations, mortality, and adverse events is unknown. | GCA/SCIENCE PHOTO LIBRARY

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package